River Stone uses synthetic biology to enable new pharmaceutical approaches.
We are focused on three areas

CNS

Rethinking how CNS actives are made, in particular molecules for treating addiction

READ MORE

IN SITU

Making small molecule APIs inside the body. Enables entirely new ways of treating disease

READ MORE

GLY-IT

Altering small molecule ADMET and tissue distribution via saccharide decoration

READ MORE

PIONEERING SYNTHETIC BIOLOGY

River Stone was founded in 2016 with a focus on API production route re-engineering.  Our team has a track record in building pioneering synthetic biology and life science ventures.  The team has brought multiple synbio and pharma products to market.

READ MORE

SENIOR TEAM

CONTACT AND INFORMATION

For questions regarding commercial partnerships and investors and collaboration with academic partners, please contact us. Feel free to call on us anytime.

READ MORE